5-硝基-2-吡啶羧酸 | 30651-24-2

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-硝基-2-吡啶羧酸
• 中文别名: 5-硝基-2-吡啶甲酸；5-硝基吡啶-2-甲酸；2-羧酸-5-硝基吡啶
• 英文名称: 5-nitropicolinic acid
• 英文别名: 5-nitropyridine-2-carboxylic acid；5-Nitropicolinsaeure；5-Nitropyridin-2-carbonsaeure；5-Nitro-2-pyridin-carbonsaeure；5-nitro-2-pyridinecarboxylic acid
• CAS: 30651-24-2
• 化学式: C₆H₄N₂O₄
• mdl: MFCD04114182
• 分子量: 168.109
• InChiKey: QKYRCTVBMNXTBT-UHFFFAOYSA-N

物化性质

• 熔点：
  218-220°C
• 沸点：
  389.8±27.0 °C(Predicted)
• 密度：
  1.570±0.06 g/cm3(Predicted)
• 溶解度：
  溶于二甲基亚砜。

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  96
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R22,R20/21/22,R36/37/38
• 海关编码：
  2933399090
• 危险品运输编号：
  NONH for all modes of transport
• 危险标志：
  GHS07
• 危险性描述：
  H302
• 危险性防范说明：
  P261,P305+P351+P338
• 储存条件：
  -20°C 冰箱

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
5-Nitropicolinic acid
Product Name:
Synonyms: 5-Nitropyridine-2-carboxylic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
5-Nitropicolinic acid
Ingredient name:
CAS number: 30651-24-2

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H4N2O4
Molecular weight: 168.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

5-硝基-2-吡啶羧酸是一种羧酸类衍生物，可用作有机中间体。其合成方法是从丙二酸二乙酯和2-氯-5-硝基吡啶出发，首先制备2-(5-硝基吡啶基)-丙二酸二乙酯，再与硝酸反应得到目标产物。

反应信息

• 作为反应物：
  描述：

  5-硝基-2-吡啶羧酸 在 ammonium hydroxide 、 硫化氢 作用下， 以86%的产率得到5-氨基-2-吡啶羧酸
  参考文献：
  名称：

  Comparison of two synthetic methods to obtain [18F] N-(2-aminoethyl)-5-fluoropyridine-2-carboxamide, a potential MAO-B imaging tracer for PET

  摘要：

  化合物Ro 19-6327，即N-(2-氨基乙基)-5-氯吡啶-2-甲酰胺，已知能可逆且特异性地抑制单胺氧化酶B（MAO-B）。其123I标记的碘类似物N-(2-氨基乙基)-5-碘吡啶-2-甲酰胺（Ro 43-0463）已成功通过单光子发射断层扫描（SPET）在人体志愿者中进行了研究。因此，我们开发了相应的氟类似物N-(2-氨基乙基)-5-氟吡啶-2-甲酰胺与18F的合成及放射性标记，以进行正电子发射断层扫描（PET）研究与MAO-B相关的神经精神疾病。为此，我们采取了两种合成途径以实现18F放射性标记的亲电法和亲核法。当考虑到前体合成、束流时间、比活度和放射化学纯度等因素时，亲核法显示出优势。

  DOI：

  10.1002/jlcr.2580361005
• 作为产物：
  描述：

  2-溴-5-硝基吡啶 在 copper(l) cyanide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.25h， 生成 5-硝基-2-吡啶羧酸
  参考文献：
  名称：

  [EN] DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS
  [FR] DÉRIVÉS DE QUINOLÉINES ET DE QUINOXALINES EN TANT QU'INHIBITEURS DE PROTÉINE TYROSINE KINASES

  摘要：

  该发明涉及式（I）的化合物，其中取代基如规范中定义的那样，以自由形式或作为药用盐、溶剂合物、酯、其N-氧化物的形式存在；其制备方法；含有这种化合物的药物，特别是用于治疗一个或多个蛋白酪氨酸激酶介导的疾病。

  公开号：

  WO2009141386A1

文献信息

• [EN] SUBSTITUTED OXOPYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS D'OXOPYRIDINE SUBSTITUÉS
  申请人：BAYER PHARMA AG

  公开号：WO2017005725A1

  公开（公告）日：2017-01-12

  The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and o edemas, and also ophthalmic disorders.

  这项发明涉及替代氧吡啶衍生物及其制备方法，以及它们用于制备治疗和/或预防疾病的药物，特别是心血管疾病，最好是血栓性或血栓栓塞性疾病，以及水肿和眼科疾病。
• Selective Chemical Functionalization at N6-Methyladenosine Residues in DNA Enabled by Visible-Light-Mediated Photoredox Catalysis
  作者：Manuel Nappi、Alexandre Hofer、Shankar Balasubramanian、Matthew J. Gaunt

  DOI：10.1021/jacs.0c10616

  日期：2020.12.23

  Selective chemistry that modifies the structure of DNA and RNA is essential to understanding the role of epigenetic modifications. We report a visible-light-activated photocatalytic process that introduces a covalent modification at a C(sp3)-H bond in the methyl group of N6-methyl deoxyadenosine and N6-methyl adenosine, epigenetic modifications of emerging importance. A carefully orchestrated reaction

  修饰 DNA 和 RNA 结构的选择性化学对于理解表观遗传修饰的作用至关重要。我们报告了一种可见光激活的光催化过程，该过程在 N6-甲基脱氧腺苷和 N6-甲基腺苷的甲基 C(sp3)-H 键上引入共价修饰，这是新兴重要性的表观遗传修饰。精心策划的反应结合了硝基吡啶的还原反应，形成亚硝基吡啶自旋捕获剂，以及精确选择性的叔胺介导的 N6-甲基上的氢原子抽象，形成 α-氨基自由基。假定的 α-氨基自由基与亚硝基吡啶交叉偶联产生稳定的缀合物，在 N6-甲基-腺苷上安装标签。我们证明，可以从复杂的混合物中富集含 N6-甲基脱氧腺苷的寡核苷酸，这为识别基因组 DNA 和 RNA 中的这种修饰的应用铺平了道路。
• [EN] HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS<br/>[FR] HÉTÉROCYCLES CONTENANT DES INHIBITEURS STAT ET COMPOSITIONS
  申请人：JANPIX LTD

  公开号：WO2021178841A1

  公开（公告）日：2021-09-10

  Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for the inhibition of Signal Transducer and Activator of Transcription 5a and 5b (STAT5). Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as, for example, breast cancer and pancreatic cancer.

  提供的是化合物和包含这些化合物的药物组合物，它们对于抑制信号转导子和转录激活子5a和5b（STAT5）有益。此外，这些主题化合物和组合物对于治疗癌症，例如乳腺癌和胰腺癌，是有用的。
• N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors
  申请人：BAGLEY SCOTT WILLIAM

  公开号：US20110111046A1

  公开（公告）日：2011-05-12

  The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R 1 , R 2 , R 3 and R 4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

  该发明提供了化合物I的化合物或其药用可接受的盐，其中R1、R2、R3和R4如本文所述；以及其药物组合物；以及在治疗受乙酰辅酶A羧化酶抑制调节的动物疾病、症状或紊乱中的使用。
• [EN] JAK1 SELECTIVE KINASE INHIBITOR<br/>[FR] INHIBITEUR SÉLECTIF DE KINASE JAK1
  申请人：DIZAL JIANGSU PHARMACEUTICAL CO LTD

  公开号：WO2020211839A1

  公开（公告）日：2020-10-22

  Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, that are useful as JAK kinase inhibitors. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula (I), and methods of using such compounds or compositions to treat respiratory conditions (e.g., asthma or COPD).

  本文披露了式（I）的化合物及其药学上可接受的盐，这些化合物可用作JAK激酶抑制剂。还披露了包含一种或多种式（I）化合物的药物组合物，以及使用这些化合物或组合物治疗呼吸道疾病（例如哮喘或慢性阻塞性肺病）的方法。

表征谱图